专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5550138A Condensed thiadiazole derivative, method of its production, and use thereof 失效
标题翻译：缩合噻二唑衍生物，其制备方法及其用途
公开(公告)号：US5550138A
公开(公告)日：1996-08-27
申请号：US039579
申请日：1993-03-23
申请人： Takashi Sohda , Zen-ichi Terashita , Yu Momose , Yukio Fujisawa , Junji Mizoguchi
发明人： Takashi Sohda , Zen-ichi Terashita , Yu Momose , Yukio Fujisawa , Junji Mizoguchi
IPC分类号： C07D513/04 , A61K31/435
CPC分类号： C07D513/04
摘要： (1) a compound represented by the following formula (I): ##STR1## wherein R represents a hydrocarbon group or heterocyclic group which may be substituted; the ring A represents a pyridine ring having a substituent or a thiazole ring which may be substituted; or a pharmaceutically acceptable salt thereof, and a method of its production, and(2) an endothelin receptor antagonist, an cathepsin B inhibitor or a bone resorption suppressor having as an active ingredient a compound represented by the following formula (I'): ##STR2## wherein R has the same definition as in term (1); the ring A' represents a pyridine ring or thiazole ring which may be substituted; or a pharmaceutically acceptable salt thereof.
摘要翻译：（1）由下式（I）表示的化合物：其中R表示可被取代的烃基或杂环基; 环A表示具有取代基的吡啶环或可被取代的噻唑环; 或其药学上可接受的盐及其制备方法，和（2）作为活性成分的下式（I'）表示的化合物的内皮素受体拮抗剂，组织蛋白酶B抑制剂或骨吸收抑制剂：（I'）其中R与术语（1）具有相同的定义; 环A'表示可被取代的吡啶环或噻唑环; 或其药学上可接受的盐。

2. 发明授权

US5955491A Method for treating osteoporosis 失效
标题翻译：治疗骨质疏松症的方法
公开(公告)号：US5955491A
公开(公告)日：1999-09-21
申请号：US495352
申请日：1995-06-27
申请人： Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
发明人： Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
IPC分类号： A61K38/55 , A61K31/16 , A61K31/165 , A61K31/18 , A61K31/27 , A61K38/00 , A61P3/00 , A61P3/02 , A61P43/00 , C07C231/12 , C07C233/18 , C07C233/22 , C07C233/31 , C07C237/10 , C07C237/22 , C07C271/16 , C07C271/18 , C07C271/22 , C07C303/40 , C07C311/19 , C07C337/02 , C07D209/14 , C07D209/16 , C07K1/113 , C07K5/06 , C07K5/062 , C07K14/81 , A61K31/405 , A61K31/195 , A61K31/41 , A61K31/435 , A61K31/495
CPC分类号： C07D209/16 , C07C233/18 , C07C233/22 , C07C233/31 , C07C271/16 , C07C271/18 , C07C271/22 , C07C311/19 , C07K5/06034 , A61K38/00 , Y02P20/55
摘要： The present invention provides a cathepsin L inhibitor containing a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R.sup.2 and R.sup.3 independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R.sup.4 is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: --CHO or --CH.sub.2 OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R.sup.4 is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R.sup.1 is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R.sup.2 and R.sup.3 independently are a lower alkyl or arylalkyl, X is --CHO, m is 1 and n is 0 or 1, or a salt thereof.
摘要翻译：本发明提供了含有下式化合物的组织蛋白酶L抑制剂：其中R1是氢原子或可被取代的芳基烷基，杂环烷基或低级烷基; R2和R3独立地是氢原子或可以被取代的烃残基; R4是可以被取代的烷酰基，磺酰基，羰基氧基，氨基甲酰基或硫代氨基甲酰基; X是式：-CHO或-CHOOB（其中B是氢原子或羟基保护基）; m和n独立地为0或1的整数; 条件是R4是被芳基取代的烷酰基，被具有多于9个碳原子的芳基取代的磺酰基或低级烷基，或当R 1是未取代的低级烷基时可被取代的氨基甲酰基或硫代氨基甲酰基，甲基硫代乙基上的芳基烷基，R2和R3独立地是低级烷基或芳烷基，X是-CHO，m是1，n是0或1，或其盐。

3. 发明授权

US5496834A Lactol derivatives, their production and use 失效
标题翻译：乳糖衍生物，其生产和使用
公开(公告)号：US5496834A
公开(公告)日：1996-03-05
申请号：US300738
申请日：1994-09-02
申请人： Takashi Sohda , Yukio Fujisawa , Satoru Oi , Junji Mizoguchi
发明人： Takashi Sohda , Yukio Fujisawa , Satoru Oi , Junji Mizoguchi
IPC分类号： A61K38/00 , C07K5/06 , C07K5/078 , A61K31/44 , A61K31/35 , A61K31/40
CPC分类号： C07K5/06139 , C07K5/06043 , A61K38/00
摘要： The present invention provides novel compound of the formulas (Ia) or (I): ##STR1## wherein Q is one or two amino acid residues which may be substituted; R.sup.3 is a carboxyl group which may be esterified or an acyl group; A is an alkylene group; B is hydrogen or an alkyl group which may be substituted or an acyl group; or a salt thereof; ##STR2## wherein R.sup.1 and R.sup.2 may be the same or different and each is hydrogen or a hydrocarbon residue which may be substituted; R.sup.3, A and B have the same definitions as those shown above; m and n each is 0 or 1; provided that where both m and n are both equal to 0, R.sup.3 is a carboxyl group which may be esterified or an acyl group having not less than 7 carbon atoms; or a salt thereof.The compound (Ia) or (I) shows cathepsin L inhibitory and bone resorption inhibitory activities and are useful as a prophylactic/therapeutic agent for osteoporosis.
摘要翻译：本发明提供新的式（Ia）或（I）化合物：其中Q是一个或两个可被取代的氨基酸残基; R3是可被酯化的羧基或酰基; A是亚烷基; B是氢或可以被取代的烷基或酰基; 或其盐; （I）其中R 1和R 2可以相同或不同，各自为氢或可被取代的烃残基; R3，A和B具有与上述相同的定义; m和n各自为0或1; 条件是当m和n都等于0时，R 3是可被酯化的羧基或具有不少于7个碳原子的酰基; 或其盐。化合物（Ia）或（I）表示组织蛋白酶L抑制和骨吸收抑制活性，可用作骨质疏松症的预防/治疗剂。

4. 发明授权

US5716980A Alcohol or aldehyde derivatives and their use 失效
标题翻译：酒精或醛衍生物及其用途
公开(公告)号：US5716980A
公开(公告)日：1998-02-10
申请号：US495097
申请日：1995-06-27
申请人： Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
发明人： Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
IPC分类号： A61K38/55 , A61K31/16 , A61K31/165 , A61K31/18 , A61K31/27 , A61K38/00 , A61P3/00 , A61P3/02 , A61P43/00 , C07C231/12 , C07C233/18 , C07C233/22 , C07C233/31 , C07C237/10 , C07C237/22 , C07C271/16 , C07C271/18 , C07C271/22 , C07C303/40 , C07C311/19 , C07C337/02 , C07D209/14 , C07D209/16 , C07K1/113 , C07K5/06 , C07K5/062 , C07K14/81 , A61K31/40 , C07D209/20
CPC分类号： C07D209/16 , C07C233/18 , C07C233/22 , C07C233/31 , C07C271/16 , C07C271/18 , C07C271/22 , C07C311/19 , C07K5/06034 , A61K38/00 , Y02P20/55
摘要： The present invention provides a cathepsin L inhibitor containing a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R.sup.2 and R.sup.3 independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R.sup.4 is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: --CHO or --CH.sub.2 OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R.sup.4 is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R.sup.1 is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R.sup.2 and R.sup.3 independently are a lower alkyl or arylalkyl, X is --CHO, m is 1 and n is 0 or 1, or a salt thereof. Compound (I) is useful as a prophylactic/therapeutic agent for osteoporosis.
摘要翻译：本发明提供了含有下式化合物的组蛋白酶L抑制剂：其中R1是氢原子或可被取代的芳基烷基，杂环烷基或低级烷基; R2和R3独立地是氢原子或可以被取代的烃残基; R4是可以被取代的烷酰基，磺酰基，羰基氧基，氨基甲酰基或硫代氨基甲酰基; X是式：-CHO或-CHOOB（其中B是氢原子或羟基保护基）; m和n独立地为0或1的整数; 条件是R4是被芳基取代的烷酰基，被具有多于9个碳原子的芳基取代的磺酰基或低级烷基，或当R 1是未取代的低级烷基时可被取代的氨基甲酰基或硫代氨基甲酰基，甲基硫代乙基上的芳基烷基，R2和R3独立地是低级烷基或芳烷基，X是-CHO，m是1，n是0或1，或其盐。化合物（I）可用作骨质疏松症的预防/治疗剂。

5. 发明授权

US5639781A Alcohol or aldehyde derivatives and their use 失效
标题翻译：酒精或醛衍生物及其用途
公开(公告)号：US5639781A
公开(公告)日：1997-06-17
申请号：US495814
申请日：1995-06-27
申请人： Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
发明人： Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
IPC分类号： A61K38/55 , A61K31/16 , A61K31/165 , A61K31/18 , A61K31/27 , A61K38/00 , A61P3/00 , A61P3/02 , A61P43/00 , C07C231/12 , C07C233/18 , C07C233/22 , C07C233/31 , C07C237/10 , C07C237/22 , C07C271/16 , C07C271/18 , C07C271/22 , C07C303/40 , C07C311/19 , C07C337/02 , C07D209/14 , C07D209/16 , C07K1/113 , C07K5/06 , C07K5/062 , C07K14/81 , A61K31/40 , C07D209/08
CPC分类号： C07D209/16 , C07C233/18 , C07C233/22 , C07C233/31 , C07C271/16 , C07C271/18 , C07C271/22 , C07C311/19 , C07K5/06034 , A61K38/00 , Y02P20/55
摘要： The present invention provides a cathepsin L inhibitor containing a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R.sup.2 and R.sup.3 independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R.sup.4 is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: --CHO or --CH.sub.2 OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R.sup.4 is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R.sup.1 is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R.sup.2 and R.sup.3 independently are a lower alkyl or arylalkyl, X is --CHO, m is 1 and n is 0 or 1, or a salt thereof.Compound (I) is useful as a prophylactic/therapeutic agent for osteoporosis.
摘要翻译：本发明提供了含有下式化合物的组蛋白酶L抑制剂：其中R1是氢原子或可被取代的芳基烷基，杂环烷基或低级烷基; R2和R3独立地是氢原子或可以被取代的烃残基; R4是可以被取代的烷酰基，磺酰基，羰基氧基，氨基甲酰基或硫代氨基甲酰基; X是式：-CHO或-CHOOB（其中B是氢原子或羟基保护基）; m和n独立地为0或1的整数; 条件是R4是被芳基取代的烷酰基，被具有多于9个碳原子的芳基取代的磺酰基或低级烷基，或当R 1是未取代的低级烷基时可被取代的氨基甲酰基或硫代氨基甲酰基，甲基硫代乙基上的芳基烷基，R2和R3独立地是低级烷基或芳烷基，X是-CHO，m是1，n是0或1，或其盐。化合物（I）可用作骨质疏松症的预防/治疗剂。

6. 发明授权

US5498728A Derivatives of L-tryptophanal and their use as medicinals 失效
标题翻译： L-色氨酸的衍生物及其作为药物的用途
公开(公告)号：US5498728A
公开(公告)日：1996-03-12
申请号：US192038
申请日：1994-02-04
申请人： Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
发明人： Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
IPC分类号： A61K38/55 , A61K31/16 , A61K31/165 , A61K31/18 , A61K31/27 , A61K38/00 , A61P3/00 , A61P3/02 , A61P43/00 , C07C231/12 , C07C233/18 , C07C233/22 , C07C233/31 , C07C237/10 , C07C237/22 , C07C271/16 , C07C271/18 , C07C271/22 , C07C303/40 , C07C311/19 , C07C337/02 , C07D209/14 , C07D209/16 , C07K1/113 , C07K5/06 , C07K5/062 , C07K14/81 , A61K31/40
CPC分类号： C07D209/16 , C07C233/18 , C07C233/22 , C07C233/31 , C07C271/16 , C07C271/18 , C07C271/22 , C07C311/19 , C07K5/06034 , A61K38/00 , Y02P20/55
摘要： The present invention provides a cathepsin L inhibitor containing a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R.sup.2 and R.sup.3 independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R.sup.4 is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: --CHO or --CH.sub.2 OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R.sup.4 is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R.sup.1 is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R.sup.2 and R.sup.3 independently are a lower alkyl or arylalkyl, X is --CHO, m is 1 and n is 0 or 1, or a salt thereof.Compound (I) is useful as a prophylactic/therapeutic agent for osteoporosis.
摘要翻译：本发明提供了含有下式化合物的组蛋白酶L抑制剂：其中R1是氢原子或可被取代的芳基烷基，杂环烷基或低级烷基; R2和R3独立地是氢原子或可以被取代的烃残基; R4是可以被取代的烷酰基，磺酰基，羰基氧基，氨基甲酰基或硫代氨基甲酰基; X是式：-CHO或-CHOOB（其中B是氢原子或羟基保护基）; m和n独立地为0或1的整数; 条件是R4是被芳基取代的烷酰基，被具有多于9个碳原子的芳基取代的磺酰基或低级烷基，或当R 1是未取代的低级烷基时可被取代的氨基甲酰基或硫代氨基甲酰基，甲基硫代乙基上的芳基烷基，R2和R3独立地是低级烷基或芳烷基，X是-CHO，m是1，n是0或1，或其盐。化合物（I）可用作骨质疏松症的预防/治疗剂。

7. 发明授权

US5614544A Oxazolidinedione derivatives and their use 失效
标题翻译：恶唑二酮衍生物及其用途
公开(公告)号：US5614544A
公开(公告)日：1997-03-25
申请号：US303209
申请日：1994-09-08
申请人： Takashi Sohda , Hitoshi Ikeda , Yu Momose
发明人： Takashi Sohda , Hitoshi Ikeda , Yu Momose
IPC分类号： C07D263/44 , C07D413/14 , C07D417/10 , A61K31/42
CPC分类号： C07D263/44 , C07D413/14 , C07D417/10
摘要： [Object]To provide a new 2,4-oxazolidinedione derivative possessing excellent hypoglycemic and hypolipidemic activities.[Constituent]A 2,4-oxazolidinedione derivative represented by the general formula: ##STR1## wherein X represents --CH.sub.2 --, --C(.dbd.O)--, --CH(OH)--, --C(.dbd.NOH)-- or --CH.dbd.CH--; R represents a hydrocarbon residue or heterocyclic group which may be substituted; n represents an integer from 0 to 5, and m represents an integer from 1 to 3; ....... represents a single or double bond; provided that n is an integer from 1 to 5 when X is --C(.dbd.O)--, or a pharmacologically acceptable salt thereof.[Drawings selected]None
摘要翻译： [目的]提供具有优异的降血糖和降血脂活性的新的2,4-恶唑烷二酮衍生物。 [组成成分]下列通式表示的2,4-恶唑烷二酮衍生物：其中X代表-CH2-，-C（= O） - ， - CH（OH） - ， - C（= NOH） CH = CH-; R表示可以被取代的烃残基或杂环基; n表示0〜5的整数，m表示1〜3的整数， + E，uns ....... + EE表示单键或双键; 条件是当X为-C（= O） - 时，n为1至5的整数，或其药理学上可接受的盐。 [已选图纸]无

8. 发明授权

US5371098A Use of oxazole compounds to treat osteoporosis 失效
标题翻译：使用恶唑化合物治疗骨质疏松症
公开(公告)号：US5371098A
公开(公告)日：1994-12-06
申请号：US929097
申请日：1992-08-13
申请人： Takashi Sohda , Iwao Yamazaki , Yu Momose
发明人： Takashi Sohda , Iwao Yamazaki , Yu Momose
IPC分类号： A61K31/42 , A61K31/421 , A61K31/422 , A61P3/00 , A61P3/02 , A61P19/08 , A61P19/10 , A61P43/00 , C07D263/32 , C07D263/34 , C07D413/12 , C07D417/12 , C07D263/30
CPC分类号： C07D263/32
摘要： An oxazole compound having the formula (I): ##STR1## in which A is a group of the formula --CH.sub.2 OR.sup.2 (wherein R.sup.2 is a hydrogen atom, an optionally substituted hydrocarbon residue, an optionally substituted heterocyclic group or an acyl group) or an aldehyde group, B is an optionally substituted phenyl group, R.sup.1 is a hydrogen atom or an optionally substituted alkyl group, and n is an integer of 0 to 6, provided that when n is 2, R.sup.1 is an optionally substituted alkyl group, or its salt, which is useful as a therapeutic agent for metabolic bone diseases including osteoporosis.
摘要翻译：具有式（I）的恶唑化合物：其中A是式-CH 2 OR 2的基团（其中R 2是氢原子，任选取代的烃残基，任选取代的杂环基或酰基））或醛基，B为任选取代的苯基，R 1为氢原子或任选取代的烷基，n为0〜6的整数，条件是当n为2时，R 1为任选取代的烷基或其盐，其可用作包括骨质疏松症在内的代谢性骨疾病的治疗剂。

9. 发明授权

US06552058B1 Oxazolidinedione derivatives and their use 失效
标题翻译：恶唑二酮衍生物及其用途
公开(公告)号：US06552058B1
公开(公告)日：2003-04-22
申请号：US09667247
申请日：2000-09-22
申请人： Takashi Sohda , Hitoshi Ikeda , Yu Momose , Sachiko Imai
发明人： Takashi Sohda , Hitoshi Ikeda , Yu Momose , Sachiko Imai
IPC分类号： C07D26318
CPC分类号： C07D263/44 , C07D413/12 , C07D413/14 , C07D417/12
摘要： Novel 2,4-oxazolidinedione compounds of the formula: wherein R is a hydrocarbon residue or a heterocyclic group each of which may be substituted; Y is —CO—, —CH(OH)— or —NR3— (wherein R3 is an alkyl group which may be substituted); m is 0 or 1; n is 0, 1 or 2; X is CH or N; A is bivalent straight or branched hydrocarbon chain residue having 1 to 7 carbon atoms; R1 and R2 each are hydrogen or an alkyl group, or R1 and R2 are combined with each other to form a 5- to 6-membered heterocyclic group optionally containing nitrogen; L and M each are hydrogen, or L and M are combined with each other to form a bond, or pharmaceutically acceptable salts thereof, having excellent hypoglycemic and hypolipidemic activities and are useful as anti-diabetics or hypolipidemic agents.
摘要翻译：下式的新型2,4-恶唑烷二酮化合物：其中R是可以被取代的烃残基或杂环基; Y是-CO - ， - CH（OH） - 或-NR 3 - （其中R 3是可被取代的烷基）; m为0或1; n为0,1或2; X是CH或N; A是具有1至7个碳原子的二价直链或支链烃链残基; R 1和R 2各自为氢或烷基，或者R 1和R 2彼此结合形成任选含有氮的5至6元杂环基; L和M各自为氢，或L和M彼此结合以形成具有优异的降血糖和降血脂活性的键或其药学上可接受的盐，并且可用作抗糖尿病药或降血脂药。

10. 发明授权

US06365607B1 Anticachectic composition 失效
标题翻译：防寒组成
公开(公告)号：US06365607B1
公开(公告)日：2002-04-02
申请号：US09605628
申请日：2000-06-28
申请人： Yu Momose , Etsuya Matsutani , Takashi Sohda
发明人： Yu Momose , Etsuya Matsutani , Takashi Sohda
IPC分类号： A61K3144
CPC分类号： A61K31/4439 , A61K31/422 , A61K31/427
摘要： A medicinal composition for the prophylaxis and treatment of cachexia which comprises a compound of the formula: wherein R represents a hydrocarbon group that may be substituted or a heterocyclic group that may be substituted; Y represents a group of the formula —CO—, —CH(OH)—, or —NR3— (R3 represents an alkyl group that may be substituted); m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulfur; R1 represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with R1; L and M respectively represent hydrogen or may be combined with each other to form a bond, provided that when m and n are 0, X represents CH, A represents a bond, Q represents sulfur, R1, L and M respectively represent hydrogen, and ring E does not have further substituents, R does not represent dihydrobenzopyranyl; or a salt thereof.
摘要翻译：一种用于预防和治疗恶病质的药物组合物，其包含下式化合物：其中R表示可被取代的烃基或可被取代的杂环基; Y表示式-CO-，-CH（OH） - 或-NR 3 - （R 3表示可被取代的烷基）的基团; m为0或1; n为0,1或2; X表示CH或N; A表示碳原子数1〜7的键或2价脂肪族烃基， Q表示氧或硫; R1表示氢或烷基; 环E可以具有另外1至4个取代基，其可以与R 1组合形成环; L和M分别表示氢或可以彼此结合形成键，条件是当m和n为0时，X表示CH，A表示键，Q表示硫，R 1，L和M表示氢，环E不具有其它取代基，R不表示二氢苯并吡喃基; 或其盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式